Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions

This publication has 27 references indexed in Scilit:

• Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety study
  Journal of the American College of Cardiology, 2003
• Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects
  European Journal of Clinical Pharmacology, 2003
• A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I
  Journal of Thrombosis and Haemostasis, 2003
• Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial
  The Lancet, 2002
• Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty
  Annals of Internal Medicine, 2002
• Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement
  Archives of internal medicine (1960), 2001
• Is diclofenac a valuable CYP2C9 probe in humans?
  European Journal of Clinical Pharmacology, 2001
• Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis
  Fibrinolysis and Proteolysis, 1997
• Role of Cytochrome P450 Enzymes in Drug-Drug Interactions
  Published by Elsevier ,1997
• Diazepam metabolism by human liver microsomes is mediated by both S‐ mephenytoin hydroxylase and CYP3A isoforms.
  British Journal of Clinical Pharmacology, 1994